Drug intelligence / Profile preview

SOL-258

Development stage: Preclinical
Lead developer: Sola Biosciences
Modality: Gene Therapies

Overview

SOL-258 is an investigational gene therapy developed by Sola Biosciences. It is being studied for the treatment of neurodegenerative diseases, with primary indications including Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The drug utilizes a gene therapy modality, but specific details about its vector, transgene, or precise mechanism of action have not been disclosed in public sources. As of the latest updates, SOL-258 remains in preclinical development and has not received regulatory approval for any indication[1][2].

Beyond the preview

Go deeper on SOL-258.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOL-258.

Explore the full profile